Introduction
PU.1, an Ets family transcription factor, was originally identified as a protein binding to a purine-rich sequence (PU-Box) in the promoter region of mouse major histocompatibility complex (MHC) class II I-Ab gene (Klemsz et al., 1990 ). Subsequently, it was shown that PU.1 was identical to the product of Spi-1 oncogene which is activated in Friend virus-induced murine erythroleukemia (MEL) through proviral integration (Moreau-Gachelin, 1994) . Aberrant expression of PU.1 results in development of erythroleukemia in mice (Moreau-Gachelin et al., 1996) and mice null for the PU.1 gene are lethal with lack of B cells and macrophages (Scott et al., 1994; Mc Kercher et al., 1996) , suggesting that PU.1 is implicated in hematopoietic cell growth and differentiation. PU.1 binds in a sequencespecific manner to the Ets-binding site (5 0 -GGAA/T-3 0 ) in the enhancer or promoter region of several genes, such as immunoglobulin genes in B cells (Pongubala et al., 1992; Rao et al., 1997) and the macrophage colony stimulation factor receptor (M-CSFR) gene in myelomonocytes (Zhang et al., 1994; Tenen et al., 1997) , and regulates expression of these genes.
It has been reported that PU.1 functions in concert with other transcription factors, for example, c-Myb and C/EBPa (Oelgeschlnger et al., 1996) , c-Fos (Bassuk and Leiden, 1995) , c-Jun (Pongubala and Atchison, 1997) and AML1 (Petrovick et al., 1998) , in regulation of the promoters of several myeloid-specific genes. Further, PU.1 is also known to perform its function through interaction with other partner proteins such as TATA binding protein (TBP), (Hagemeier et al., 1993) , Rb (Konishi et al., 1999) , NF-EM5/Pip (Eisenbeis et al., 1995) and NF-IL6b (C/EBPd) (Nagulapalli et al., 1995) . In line with this, we have previously demonstrated that PU.1 interacts with CREB binding protein (CBP), which functions as a coactivator of transcription factors (Yamamoto et al., 1999) . Through this interaction, the transcriptional activity of PU.1 to an artificial reporter construct containing PU.1 binding sites was upregulated. Moreover, we have also demonstrated that PU.1 binds to corepressor mSin3A and forms a complex with mSin3A and HDAC1 to downregulate the activities of various promoters without PU.1 binding sites (KiharaNegishi et al., 2001) . Given these facts, it is conceivable that PU.1 functions through unknown protein-protein interactions in some circumstances.
In this report, to find novel proteins binding to PU.1, we carried out affinity purification with a column of Glutathione-Sepharose beads bound to GST-PU.1 fusion protein and isolated MeCP2 as a binding partner of PU.1. PU.1 interacted directly with MeCP2 via its Ets domain and MeCP2 interacted with PU.1 via either its N-terminal region or trans-repression domain (TRD). Reporter assay indicated that MeCP2 represses transcriptional activity of PU.1, probably due to facilitated complex formation with mSin3A and HDAC1. Moreover, chromatin immunoprecipitation (ChIP) assay showed that PU.1 and MeCP2 colocalize at the PU.1-binding site in the chromatin molecules. These findings lead us to suppose that MeCP2 acts as a corepressor of PU.1
Results

Isolation of proteins associating with PU.1
By using affinity column chromatography, we surveyed proteins associating with PU.1 in MEL cell extracts. The purification procedure is shown in Figure 1a . Briefly, following application of cellular lysates (1 mg) of MEL cells to a column of Glutathion-Sepharose beads on which GST-PU.1 fusion protein was immobilized, PU.1-binding proteins were eluted with step-wise concentrations of NaCl (0.1, 0.5, 1.0 and 1.5 M). The eluate was then applied to the second round of purification as described above. As shown in Figure 1b , several bands were detected in SDS-PAGE of the final elute (fractions #25-28) after silver staining of the gel. The bands recognized by antibodies to known proteins to bind to PU.1, such as pRB, TBP, CBP and HDAC1, in Western blot analyses were not subjected to protein sequence analysis (data not shown). A sequence of 10 N-terminal amino acids of four samples of interest out of six examined was determined. Homology search with BLAST revealed that they were nucleolin, MeCP2, carcinoembryonic antigen (CEA) and histone H2B (Figure 1b ). Of these candidate proteins, we paid special attention to MeCP2 and studied the biological importance of the interaction between PU.1 and MeCP2 in detail. To verify the physical association between PU.1 and MeCP2, we first performed coimmunoprecipitation assay. The expression vectors of PU.1 and FLAGtagged MeCP2 were separately transfected into 293 T cells and cell lysates were prepared. The cell lysates were mixed and then subjected to coimmunoprecipitation analysis. An antibody against PU.1 co-precipitated MeCP2 and an antibody against FLAG-tag co-precipitated PU.1, respectively (Figure 2a and b) , suggesting that PU.1 and MeCP2 associate each other in vivo.
Next, to investigate whether PU.1 interacts directly with MeCP2 and to determine the region of PU.1 required for interaction with MeCP2, we performed glutathione S-transferase (GST) pull-down assay using the various deletion forms of GST-PU.1 fusion proteins ( Figure 3a) . As shown in Figure 3b , whereas the 35 Slabeled FLAG-tagged MeCP2 translated in vitro was coprecipitated with intact PU.1 (GST-PU.1 WT), PU.1 with deletion of the activation domain (GST-PU.1 DA), and PU.1 having only Ets domain (GST-PU.1 E), it was not co-precipitated with other deletion forms of PU.1. These results indicate that PU.1 interacts with MeCP2 directly and the region of Ets domain of PU.1 is sufficient for the interaction with MeCP2.
We further performed GST pull-down assay using deletion forms of GST-MeCP2 fusion proteins ( Figure 4a ) and 35 S-labeled in vitro translated PU.1 to identify the region of MeCP2 necessary for binding to Figure 2 In vivo association between PU.1 and MeCP2. (a) Western blot analysis of PU.1 using antibody against FLAG-tag (a-FLAG Ab; M2 Stratagene). Equal volume of extracts from 293 T cells transfected cells with PU.1 expression vector or a FLAG-tagged MeCP2 expression vector were mixed. The inputs were 10% of the amount of each expression vector transfected cell lysates (lanes 1-4) . In all, 500 mg of mixed lysates transfected cells were immunoprecipitated with a-FLAG Ab (lanes 5-8). Western blot analysis was performed by the antibody with PU.1. (b) Western blot analysis of MeCP2 using antibody against PU.1 (a-PU.1 Ab). Cell lysates were prepared as above and were immunoprecipitated with a-PU.1 Ab (lanes 5-8). Western blot analysis was performed using the antibody against FLAG S-labeled MeCP2 were incubated with 50% slurry of 20 ml of immobilized GST protein and GST-fusion proteins containing various deletion mutants of PU.1, and bound GST-PU.1 deletion mutant derivatives were spread to Nu-PAGE followed by autoradiography. (c) Various deletion mutant derivatives of GST-PU.1. GST-PU.1 mutants, immobilized by glutathione-beads, were analysed by Nu-PAGE followed by Coomasie brilliant blue staining Association between PU.1 and MeCP2 M Suzuki et al PU.1. PU.1 was co-precipitated with intact MeCP2 (GST-MeCP2 WT) and all of the deletion mutants but not the one having only DNA binding domain (GSTMeCP2 D) (Figure 4b ), indicating that either N-terminal region (amino acids 1-92) or TRD of MeCP2 is necessary for the interaction with PU.1.
Inhibition of transcriptional activity of PU.1 by MeCP2
The above results raised the possibility that MeCP2 affects the transcriptional activity of PU.1 because it is known that MeCP2 functions as a transcriptional corepressor through complex formation with mSin3A
and HDAC1 at promoters rich in methylated CpG (Nan et al., 1998; Jones et al., 1998) . To address this possibility, we performed luciferase reporter assay using artificial reporter constructs with or without trimerized PU.1 binding sites upstream of a thymidine kinase promoter, pTK100-PU Â 3-Luc and pTK100-Luc ( Figure 5 ). When an expression vector of PU.1 was transfected into HeLa cells with pTK100-PU Â 3-Luc reporter, reporter activity was increased about 13 fold (Figure 5a ). When intact MeCP2 (MeCP2 WT) was coexpressed with PU.1, the activity was reduced by sixfold. Whereas almost all of the MeCP2 deletion mutants (MeCP2 DN, DND, DC, DRC, DR and R) reduced the reporter activity similarly, MeCP2 D mutant which is unable to interact with PU.1 did not (Figure 5a) . Expression of PU.1 showed no effect on pTK100-Luc GST pull-down assay using GSTMeCP2 deletion mutants. In vitro-translated 35 S-labeled PU.1 were incubated with 50% sully of 20 ml of immobilized GST protein and GST-fusion proteins containing various deletion mutants of MeCP2 and bound GST-MeCP2 deletion mutant derivatives were spread to Nu-PAGE followed by autoradiography. (c) Various deletion mutant derivatives of GST-MeCP2. GST-MeCP2 mutants, immobilized by glutathione-beads, were analysed by Nu-PAGE followed by Coomasie brilliant blue staining reporter and expression of intact or deletion mutants of MeCP2 alone showed no effects on both pTK100-PU Â 3-Luc and pTK100-Luc reporter constructs. Moreover, cotransfection of increasing amounts of the expression vectors of intact MeCP2 or MeCP2 DND, but not MeCP2 D, with expression vector of PU.1 resulted in reduction of the reporter activity in a dosedependent manner (Figure 5b ). These results suggest that MeCP2 contradicts the PU.1-mediated transcriptional activation through association with PU.1.
Rescue from MeCP2-mediated repression of transcriptional activity of PU.1 by TSA Considering that MeCP2 recruits mSin3A and HDAC1 to repress the activities of promoters rich in methylated CpG, we speculated that MeCP2-mediated trans-repression on pTK100-PU Â 3-Luc depends on histone deacetylase activity in the mSin3A-HDAC1 complex bound to MeCP2. This possibility was examined by reporter assay performed in the presence of trichostatin A (TSA), a histone deacetylase-specific inhibitor.
HeLa cells were transfected with expression vectors of PU.1 and MeCP2 WT and pTK100-PU Â 3-Luc reporter with increasing amounts of TSA. MeCP2-dependent trans-repression was rescued by addition of TSA in a dose-dependent manner ( Figure 6 ). When 100 nM of TSA was given to the cells, the trans-activation level was recovered up to an almost identical level (about 11-fold) achieved by PU.1 alone, suggesting that the transrepressional activity of MeCP2 is dependent on the histone deacetylase activity in mSin3A-HDAC1 complex associated with MeCP2.
Preferential association of PU.1 and MeCP2 with mSin3a-HDAC1 complex
From the results of reporter assay with TSA, it was supposed that PU.1 and MeCP2 are integrated in an mSin3A-HDAC1 complex. On the other hand, we previously reported that CBP binds to PU.1 and upregulates its transcriptional activity at least under some circumstances (Yamamoto et al., 1999) . These results raised an interesting question as to which complex, PU.1-mSin3A-HDAC1 or PU.1-CBP, is preferentially formed in the presence of MeCP2. To clarify this point, we performed pull-down assay using in vitro translated (IVT) recombinant proteins of PU.1, MeCP2, mSin3A, HDAC1 and CBP.
IVT-PU.1 and IVT-MeCP2 were coimmunoprecipitated with IVT-HA-HDAC1 and IVT-mSin3A by an anti-HA antibody in the presence of IVT-mSin3A (Figure 7a, lanes 13-16) . In contrast, IVT-PU.1 and IVT-MeCP2 were not coimmunoprecipitated with IVT-HA-HDAC1 in the absence of IVT-mSin3A (Figure 7a , lanes 9-12). Moreover, immunoprecipitates of IVT-PU.1 and IVT-MeCP2 were increased by addition of IVTmSin3A in a dose-dependent manner ( Figure 7b , lanes 1-3). These results suggest that HDAC1 is unable to associate with PU.1 and MeCP2 directly and that mSin3A facilitates association of HDAC1 with PU.1 and MeCP2 a similar experiment showed that IVT-PU.1, but not IVT-MeCP2, was coimmunoprecipitated with IVT-FLAG-CBP by an anti-FLAG antibody (Figure 7d , lanes 9-11), suggesting that MeCP2 is not integrated in the PU.1-CBP complex. Next, to address whether MeCP2 recruits mSin3A-HDAC1 complex to PU.1, competitive assay was done. The immunoprecipitates of IVT-PU.1, but not IVT-CBP1890, were decreased by addition of cold nonradio-labeled IVTmSin3A in a dose-dependent manner only in a presence of IVT-MeCP2 (Figure 7e , compare lanes 1-3 with lanes 4-6). On the other hand, the immunoprecipitates of IVT-PU.1, IVT-MeCP2, IVT-mSin3A and IVT-HDAC1 were invariable irrespective of an increased dose of unlabeled IVT-CBP (Figure 7c, lanes 1-3) . Taken together, these results suggest that MeCP2 preferentially forms a complex with PU.1, mSin3A and HDAC1. The above results strongly suggest that complex formation between PU.1 and MeCP2 represses the PU.1-mediated activity in the promoter containing PU.1 binding sites. To determine whether PU.1 and MeCP2 are colocalized at the PU.1 binding site in the chromatin molecules, we performed chromatin immunoprecipitation (ChIP) assays. Expression vectors of PU.1 and wild type of MeCP2 (MeCP2 WT) or two of the deletion mutants (MeCP2 DND and MeCP2 D) were transfected with the reporter vector, pTK100-Luc or pTK100-PU Â 3-Luc, into 293 T cells. After immunoprecipitation, the target DNA sequence of PU.1 site between the thymidine kinase promoter region and the luciferase gene was amplified by PCR using specific primers. The chromatin immunoprecipitates obtained with an antibody against PU.1 from all of the cells cotransfected with PU.1 and MeCP2 WT or two of the MeCP2 mutants were enriched for the chromatin including the DNA sequence of the PU.1 binding site when pTK100-PU Â 3-Luc vector was used as a reporter (Figure 8a,  lanes 9-12) . In contrast, the chromatin immunoprecipitates obtained with the antibody against FLAG from the cells cotransfected with PU.1 and MeCP2 WT or MeCP2 DND mutant (Figure 8a, lanes 14 and 15) , but not from the cells cotransfected with PU.1 and MeCP2 D mutant were enriched for the chromatin including the DNA sequence of the PU.1 binding site (Figure 8a , lane 16). When pTK-100-Luc vector having no PU.1 binding site was cotransfected as a reporter gene, amplification of the sequence of the PU.1 binding site was not detected in the chromatin immunoprecipitates obtained by either of the antibodies (Figure 8b, lanes 9-16) . These results indicate that MeCP2 binds to and colocalizes with PU.1 at the PU.1-binding site in the chromatin molecule.
Colocalization of PU.1 and MeCP2 in the b-globin IVS2 region in murine erythroleukemia (MEL) cells
We next sought to determine the biological significance of the complex formation of MeCP2 with PU.1 at the PU.1-binding site in vivo. To this end, we utilized murine erythroleukemia (MEL) cells as a model system, because it is known that PU.1 binds to a DNaseI-hypersensitive site in the intervening sequence 2 (IVS2) region in the intron of the b-globin gene, which is supposed to be S-labeled FLAG-tagged CBP 1890 (IVT-FL-CBP) and unlabeled in vitro translated mSin3A (IVT-mSin3A, indicated by outline character) were also synthesized as described above. Each in vitro translate was mixed as indicated. Input proteins corresponding to 10% of total amount of proteins were used for immunoprecipitation and were spread by NuPAGE. Proteins immunoprecipitaed with the antibody against FLAG were analysed by NuPAGE and followed by autoradiography Association between PU.1 and MeCP2 M Suzuki et al involved in regulation of gene expression in MEL cells (Galson et al., 1993) , and that expression of the b-globin and PU.1 genes are up-and downregulated, respectively, in the course of erythroid differentiation of MEL cells induced by dimethylsulfoxide (DMSO) treatment (Yamada et al., 1997) .
In ChIP analysis, immunoprecipitates obtained with the antibody against PU.1 from MEL cells transfected with exogenous PU.1 enriched for the chromatin containing the DNA sequence amplified by PCR using primers specific for the IVS2 region. This enrichment was observed irrespective of presence of exogenous FLAGtagged MeCP2 WT or MeCP2 DND mutant (Figure 9a , lanes 2, 4 and 6 in the top panel). Immunoprecipitates obtained with anti-FLAG antibody from MEL cells transfected with exogenous MeCP2 WT alone or MeCP2 WT along with exogenous PU.1, enriched for the chromatin containing the IVS2 region (Figure 9a , lanes 3-6 in the second panel). The enrichment was not observed in MEL cells transfected with MeCP2 DND mutant, which is unable to bind to PU.1. These results support the notion that MeCP2 colocates at the PU.1 binding site through binding to PU.1.
Dissociation of PU.1-MeCP2 complex from the b-globin IVS2 region during MEL cell differentiation
In contrast to the above results, no enrichment of the IVS2 region was observed in the chromatin obtained with either of the antibodies from all of the transfectants treated with DMSO ( Figure 9a , top and second panels, lanes 7-12), suggesting that PU.1-MeCP2 complex detaches from the IVS2 region during erythroid differentiation of MEL cell. In the control experiment, the IVS2 region was not contained in the immunoprecipitates obtained with normal mouse IgG from any of the cells before or after the treatment with DMSO (Figure 9a, second panel from the bottom, lanes 1-12) .
In RT-PCR analysis, it was revealed that the expression level of the PU.1 gene was higher in the cells transfected with the expression vector of PU.1 in Figure 8 Colocalization of PU.1-MeCP2 complex in the chromatin molecules. (a) Chromatin immunoprecipitation in the cells transfected with pTK100-PU Â 3-Luc. The crosslinked cell lysates were prepared from 293 T cells cotransfected with PU.1 and FLAG-tagged MeCP2 WT, DND mutant or D mutant. Proteins immunoprecipitated with normal IgG or the antibodies against PU.1 or FLAG were de-crosslinked at 651C overnight. DNA from de-crosslinked chromatins from input lysates or immunoprecipitates were amplifed by PCR using specific primers between TK100 promoter and the luciferase gene. (b) Chromatin immunoprecipitation in the cells transfected with pTK100-Luc. Chromatin immunoprecipitation assay was performed as described above 
Discussion
In this study, we obtained four proteins, histone H2B, carcinoembryonic antigen (CEA), nucleolin and MeCP2 as binding partners of PU.1 by using affinity column purification. We extended our study on the physiological and biological significance of the interaction of PU.1 with MeCP2 and identified that PU.1 interacts directly with either N-terminal region (aa 1-92) or TRD of MeCP2 via the Ets domain. Recent reports showing that MeCP2 interacts with an mSin3A-HDAC complex via its TRD (Jones et al., 1998; Nan et al., 1998) led us to speculate that PU.1 could form a large complex with MeCP2, mSin3A and HDACs to act as a transcriptional repressor. Supporting this hypothesis, the reporter assay demonstrated that MeCP2 WT repressed the transcriptional activity of PU.1 in a dose-dependent manner on the reporter construct containing PU.1 binding sites (pTK100-PU Â 3-Luc), whereas the mutant MeCP2 D, which has the DNA binding domain of MeCP2 but is unable to interact with PU.1, did not exhibit the transrepression ability. Furthermore, in the presence of the histone deacetylase-specific inhibitor, trichostatin A (TSA), the transcriptional activity of PU.1 was recovered in a dose-dependent manner, and coimmunoprecipitation assay showed that MeCP2 were preferentially recruited to the mSin3A-HADC complex rather than the CBP/p300 complex with PU.1. Moreover, ChIP assay suggested that MeCP2 localizes at the PU.1-binding site through interacting with PU.1 in the chromatin molecule. Collectively, these results suggest that PU.1 forms a complex with MeCP2, which recruits the mSin3A and HDACs, and acts as a transcriptional repressor. MeCP2 DRC mutant, which contains the N-terminal region necessary for binding to PU.1 but lacks TDR necessary for binding to the mSin3A-HDAC complex, also repressed transcriptional activity of PU.1 in the reporter assay ( Figure 5 ). We observed that TSA exposure also recovered the transcriptional activation in this case (data not shown), suggesting that HDACs are involved in the repression of the transcriptional activity of PU.1 even in this mutant. MeCP2 DRC mutant may be able to recruit mSin3A to the N-terminal region of MeCP2 as reported by an other group (Nan et al., 1998) . Alternatively, this mutant may recruit mSin3A-HDAC through binding to PU.1, since PU.1 interacts directly with the mSin3A-HDAC1 complex through the regions surrounding the Ets domain as we previously reported (Kihara-Negishi et al., 2001) . This interaction might be implicated in the repression of PU.1 activity in this setting.
As mentioned above, we showed the direct interaction of PU.1 with mSin3A (Kihara-Negishi et al., 2001) . On the other hand, we also previously demonstrated the direct interaction of PU.1 with transcriptional coactivator CBP, which enhances transcriptional activity of PU.1 (Yamamoto et al., 1999) . Of particular interest is the regulatory mechanism of selection of interacting partners, CBP and mSin3A-HDAC, that possess opposite functions in regulation of gene expression. Binding of MeCP2 to PU.1 may facilitate formation of a complex with mSin3A and HDAC1. Otherwise, posttranslational modification of PU.1 such as phosphorylation, methylation and acetylation may be involved in the preferential recruitment of coactivator or corepressor, since there is a line of accumulated evidence showing that post-translational modification of proteins plays important roles for regulation of function of the proteins in the cases of histone proteins and transcription factors including p53 (Sakaguchi et al., 1998) , GATA-1 (Boyes et al., 1998) , NF-kB (Furia et al., 2002) and MyoD (Sartorelli et al., 1999) . It has been reported that CBP/p300 binds to phosphorylated forms of CREB (Chawla et al., 1998) , NFkB p65 (Zhong et al., 1998) and Jun (Bannister et al., 1995) or acetylated forms of MyoD (Polesskaya et al., 2000) and Ets-1 (CzuwaraLadykowska et al., 2002). The possible involvement of post-translational modification of PU.1 in selection of the binding partners is now being examined in our laboratory.
In this report, we identified that PU.1 directly interacts with MeCP2 via its Ets domain. We also examined whether the other Ets family proteins, Ets-1 and Fli-1, interact with MeCP2 by using GST pull-down assay and immunoprecipitation assay and found that Ets-1 and Fli-1 also interact with MeCP2 (data not shown), suggesting the possibility that some, if not all, Ets family proteins function not only as a transcriptional activator but also as a transcriptional suppressor.
Cytosine residues in the sequence of CpG are frequently methylated in mammalian cells (Razin and Riggs, 1980) . MeCP2 has been isolated as a binding protein that recognizes methylated CpG (Meehan and Bird, 1992) and as a transcriptional repressor with the recruitment of Sin3A/B and HDACs (Jones et al., 1998; Nan et al., 1998) . MeCP2 can bind the promoter region of methylated CpG site to repress the transcriptional activity by itself. In this study, however, MeCP2 alone did not repress the activities of pTK100-Luc and pTK100-PU Â 3-Luc significantly (Figure 5a and b) . Thus, PU.1-MeCP2 mediated transcriptional repression depends on PU.1 binding sites but not on the methylated CpG island in the reporter plasmids.
Recent works have revealed that epigenetic modification of DNA and chromatin is closely related to the variety of biological processes such as gene expression, cell differentiation and tumorigenesis (Singal and Ginder, 1999) . DNA methylation is one of the wellknown examples of the epigenetic modification and is catalysed by a group of enzymes called DNA methyltransferase (DNMTs). Among three DNMTs so far isolated, DNMT1, DNMT3a and DNMT3b, the former has been shown to function as a maintenance methylase, the latter two as a de novo DNA methylase (Robertson, 2001) , and moreover, all of them have been shown to interact directly with mSin3A-HDACs complex (Robertson et al., 2000; Rountree et al., 2000; Fuks et al., 2001; Datta et al., 2003) . Since we have recently found that DNMTs are coimmunoprecipitated with PU.1 (Suzuki et al., unpublished observation), the PU.1-MeCP2-DNMTs complex may cause not only the regulation of chromatin structure but also the regulation of site-specific DNA methylation.
We investigated the biological significance of the interaction between PU.1 and MeCP2 using MEL cells as a model system. PU.1 is highly expressed in Friend virus-induced MEL cells as the result of activation of the PU.1/Spi-1 gene through proviral integration of the spleen focus forming virus (SFFV). In the course of erythroid differentiation of MEL cells induced by exposure to DMSO, expression of PU.1 is downregulated (Schuetze et al., 1992) , and overexpression of PU.1 inhibits differentiation of the cells (Yamada et al., 1997) . PU.1 has been reported to be identified as a binding protein at the b-globin IVS2, which has been proposed as an important region for b-globin expression in MEL cells (Galson et al., 1993) . In the present study, we demonstrated by ChIP assay that PU.1 and MeCP2 colocalize at the PU.1 binding site of the region in the chromatin molecules in undifferentiated MEL cells but dissociate from the site during MEL cell differentiation. Thus, dissociation of the PU.1-MeCP2 complex may be one of the triggers for erythroid differentiation of MEL cells. This observation may also suggest that HDAC1 recruited to the PU.1-MeCP2 complex modifies acetylation status of histone proteins at the IVS2 region to inhibit expression of the b-globin gene in undifferentiated MEL cells. In this regard, it has been reported that overexpression of mSin3A inhibits erythroid differentiation (Huang and Brandt, 2000) and dissociation of HDACs from MyoD-HDAC complex is a trigger of myogenic differentiation (Mal et al., 2001) .
Whether the similar mechanisms are involved in PU.1-mediated regulation of expression of other genes or not is a subject for future studies. In conclusion, we showed in this study that MeCP2 associates with PU.1 and functions as its corepressor through recruitment of the mSin3A-HDAC1 complex.
Materials and methods
Cell culture
All the cells used in this study were maintained at 371C under 5% CO 2 in Dulbecco's modified Eagle minimum essential medium (for HeLa and 293 T cells) or RPMI-1640 medium (for MEL cells) supplemented with 10% fetal calf serum.
Purification and sequence analysis of PU.1-binding proteins A measure of 10 mg of MEL cell lysate were used for chromatography. The column used for affinity chromatography was Glutathione-Sepharose (Amersham Bioscience) conjugated GST-PU.1.
Step-wise eluation was carried out under condition with elution buffer (20 mM HEPES pH 7.9, 5 mM MgCl 2 , 1 mM EDTA, 1 mM PMSF, 1 mM DTT, 10% glycerol) containing 0.5 M NaCl, 1.0 M NaCl and 1.5 M NaCl. The eluates obtained in 1 ml volume each fraction were dialysed against binding buffer containing 0.1 M NaCl and separated with 4-12% NuPAGE MOPS system (Invitrogen).
To determine the sequences of the purified proteins, electrophoresed proteins were stained with Coomassie brilliant blue and transferred to a PVDF membrane (Immobilon-PSQ, Amersham), and then bands of interest were cut out and analysed with the protein sequencer (HP G1005A Protein Sequencing System).
Construction of vectors
Full-length mouse MeCP2 cDNA was obtained by RT-PCR from MEL cells using following primers. Forward-1 (from 1 to 19 nt); 5 0 -GGGAATTCATGGTAGCTGGGATGTTAGGG-3 0 (BamHI site is underlined), and reverse-1 (from 1439 to 1458 nt); 5 0 -ACGCGTCGACGTCAGCTAACTCTCTCG GTC-3 0 (SalI site is underlined). The PCR product was digested with BamHI and SalI and was subcloned in frame into pCMV-FLAG-vector (Stratagene) or pCMV-HA-vector using the BamHI and SalI sites.
The expression vectors of GST-fusion protein were constructed by subcloning of the MeCP2 gene in frame into pGEX4T-1 vector (Amersham Bioscience). The cDNA fragments of MeCP2 deletion mutants were obtained by RT-PCR using the combination of following primers, forward-1 as indicated above, forward-2 (from 276 to 295 nt); 5 0 -GGGAATTCATGGTAGCTGGGATGTTAGGG-3 0 (Bam-HI site is underlined), forward-3 (from 489 to 508 nt); 5 0 -GGGAATTCATGGTAGCTGGGATGTTAGGG-3 0 (Bam-HI site is underlined), reverse-2 (from 908 to 927 nt); 5 0 -ACGCGTCGACGTCAGCTAACTCTCTCGGTC-3 0 (SalI site is underlined), reverse-3 (from 599 to 618 nt); 5 0 -ACGCGTCGACGTCAGCTAACTCTCTCGGTC-3 0 (SalI site is underlined).
MeCP2 DD was obtained by using forward-2 primer and reverse-1 primer, MeCP2 DND by using forward-3 and reverse-1, MeCP2 DC by using forward-1 and reverse-2, MeCP2 DRC by using forward-1 and reverse-3, MeCP2 DR by using forward-2 and reverse-2, MeCP2 D by using forward-2 and reverse-3, and MeCP2 R by using forward-3 and reverse-2. The deletion mutants were also subcloned into pCMV-FLAGvector, pCMV-HA-vector or pGEX 4T-1 vector. All cloned PCR products were verified for the sequences that had no additional mutations.
The expression vector of HA-tagged PU.1 was obtained by subcloning of the PU.1 gene from pCMV-FLAG-PU.1 (Yamamoto et al., 1999) .
In vitro transcription and translation
In vitro transcription and translation were carried out by using T3 RNA polymerase and rabbit reticulocyte lysate (TNT quick-coupled transcription/translation system; Promega Bioscience, Inc.) in accordance with the supplier's suggestion. In vitro translates were labeled with 35 S-methionine.
Immunoprecipitation and immunoblotting
Cell lysates were prepared as described previously (Yamamoto et al., 1999) . Immunoprecipitation and immunoblotting were performed as described previously (Yamamoto et al., 1999) with minor modification. A measure of 500 mg of each cell lysate were immunoprecipitated with 1 mg of antibody. Each immunoprecipitate was separated with 4-12% Nu-PAGE MOPS system (Invitrogen) and then transferred onto PVDF membrane (Millipore) by a semidry blotting system. Western blotting was done using standard procedures and visualized using an ECL-PLUS (Amersham). The polyclonal antibodies to mouse PU.1 (T-21, Santa Cruz) and HA-tag (Y-11, Santa Cruz) and the monoclonal antibody to FLAG-tag (M2, Stratagene) were used.
GST pull-down assay
GST fusion proteins were expressed in E. coli DH5a and purified according to the manufacturer's directions (Amersham Bioscience). A measure of 10 mg of GST or GST fusion proteins were immobilized to Glutahione-Sepharose beads. The beads were washed extensively in a binding buffer (10 mM Tris pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, 1% NP-40, 0.1% SDS and supplement with 0.1 mM PMSF and 0.1 mM sodium vanadata as a protein inhibitor) and incubated with 10 ml of 35 S-labeled, in vitro translates generated as above for 4 h at 41C. The beads which bound proteins were washed four times by binding buffer and boiled for 2 min in 10 ml of 2 Â SDS sample buffer, and separated 4-12% Nu-PAGE MOPS systems (Invitrogen). The precipitates were detected by autoradiogram.
Luciferase assay
Cell extracts for luciferase assay were prepared as described previously (Yamamoto et al., 1999) . Vectors for reporter gene, pTK100-Luc and pTK100-PU Â 3-Luc, and an expression vector pEF-PU.1 were constructed previously (Yamamoto et al., 1999) . The pCMV-FLAG-MeCP2 deletion derivatives were constructed as described above. Each 0.1 mg of reporter vector and effecter vectors were cotransfected into HeLa cells cultured in 24-well plates. Luciferase activity was assayed with 5 ml of proteins in the cell lysate and 100 ml of pikka gene substrate (Nippongene) with the LB9501 luminometer (Berthold).
RT-PCR
Total RNA was extracted from 1 Â 10 7 cells and first-strand cDNA was obtained by incubation of 1 mg of total RNA samples with oligo dT and reverse transcriptase (Superscript II, Invitrogen) according to the manufacturer's protocol.
PCR was performed by using 1 ml of the RT-products, Ampli-Taq polymerase (Applied Biosystems) and the following primers. In all, 25-40 cycles of amplification were carried out in the following conditions for each cycle: denaturing at 941C for 1 min, annealing at 551C for 1 min and extension at 721C for 1 min. Glycelaldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The primers used were as follows: mouse GAPDH (forward), 5 0 -CCAAGGT CATCCATGACAAC-3 0 ; mouse GAPDH (reverse), 5 0 -CTGTTGCTGTAGCCGTATTC-3 0 ; mouse b-globin (forward), 5 0 -GTGCACCTGACTGATGCTG-3 0 ; mouse b-globin (reverse), 5 0 -GTGGTACTTGTGAGCCAAGG-3 0 ; mouse PU.1 (forward), 5 0 -CACAGAGCTGATGCACGTCC TCGAT-3 0 ; mouse PU.1 (reverse), 5 0 -CGGGATCCGTCTC TGCGGGCGATCAGTG-3 0 ; mouse MeCP2 (forward), 5 0 -TC CAGGAGAGCAGAAACCACC-3 0 ; mouse MeCP2 (reverse), 5 0 -CTTG-ACCTCGATGCTGACCG-3 0 . The PCR products were electrophoresed in 1% agarose gels in 1 Â TBE buffer containing ethidium bromide.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed according to Farnham Lab. with minor modifications. Crosslinked adducts with chromatin molecules were sheared by sonication, resulting in an average length of DNA ladder of 500 bp. Salmon sperm DNA/protein Aagarose (Upstate Biotech) was used instead of the Staph A cells for immunoprecipitation.
Antibodies against PU.1 and against FLAG were used as described above. Precipitated protein-DNA complexes were washed with low-salt buffer (20 mM Tris-HCl (pH 8.1), 2 mM EDTA, 150 mM NaCl, 0.1% SDS and 1% Triton X-100), highsalt buffer (20 mM Tris-HCl (pH 8.1), 2 mM EDTA, 500 mM NaCl, 0.1% SDS and 1% Triton X-100), LiCl buffer (10 mM Tris-HCl (pH 8.1), 1 mM EDTA, 250 mM LiCl, 1% NP40 and 1% DOC) and 1 Â TE, twice for each buffer. The precipitated proteins including DNA were dissolved in 1 Â TE buffer and incubated at 651C overnight to reverse crosslinks. Following RNase A, proteinase K, phenol/chloroform extraction, and ethanol precipitation, the samples were subjected to 40 cycles of PCR amplification. The primers for detection of mouse b -globin IVS2 were designed as follows; forward 5 0 -TGAG TCTGATGGGCACCTC-3 0 , reverse 5 0 -TGTGGGAATATG GAAGAACC-3 0 .
